Research Articles

If you would like to submit an article for publication in Managed Care, see our Call for papers.

Juliana Meyers, MA; Sean Candrilli, PhD; Richard Allen, PhD; Ranjani Manjunath, MPH; Michael Calloway, PhD
The researchers find that the costs of treating restless legs syndrome are fairly low, relative to the improved symptoms and associated health care outcomes, and are mainly attributable to prescription medication. Health plans are encouraged to expand coverage to reduce the associated suffering and costs.
John Barron, PharmD; Ralph Turner, PhD; Michael Jaeger, MD; Wallace Adamson, MD; Joseph Singer, MD
Patients treated with oral linezolid, covered under the pharmacy benefit, had lower re-hospitalizations and emergency room visits than patients treated with vancomycin or daptomycin, covered under the medical benefit
Setareh A. Williams, PhD; Erin K. Buysman, MS; Erin M. Hulbert, MS; Joette Gdovin Bergeson, PhD; Bin Zhang, MD; John Graham, PharmD

This study verifies, as defined by current guidelines, that initial treatment with fixed dose combinations (FDC) is associated with a better likelihood of HbA1c goal attainment and lower health care resource use and costs.

James P. Reichmann, MBA; Michael S. Kirkbride, BSc, Pharm D
A review of the available research identifies payment for services in the absence of high-quality scientific evidence and presents an opportunity to use evidence-based medicine to develop a clinical coverage guideline
Debra Wertz, PharmD; Likun Hou, MS; Andrea DeVries, PhD; Leon Dupclay Jr., PharmD, PhD; Frannie McGowan, PharmD, CDE; Barry Malinowski, MD; Mark J. Cziraky, PharmD, FAHA
The program showed significant improvements in all diabetes and hypertension-related clinical measures
Eric Q. Wu, PhD; Rym Ben-Hamadi, MSc; Mei Lu, MS; Nicolas Beaulieu, MA; Andrew P. Yu, PhD; M. Haim Erder, PhD
Escitalopram patients in a Florida Medicaid population had better treatment persistence and lower total health care costs than patients prescribed citalopram
Andrew Kolbasovsky, PsyD, MBA
Determining return on investment and improvement of outcomes is essential when new programs are being tried, but the research method must be chosen carefully
Michael Toscani, PharmD; Marc Riedl, MD, MS
With the advent of new disease-specific agents, some patients with HAE may find relief from its enormous physical and psychological toll
Anand A. Dalal, PhD; Sean D. Candrilli, PhD; Keith L. Davis, MA
The comparison found that maintenance therapy with fluticasone propionate-salmeterol combination was associated with a 14% reduction in risk of severe exacerbation, less health care utilization, and 25% lower COPD-related medical costs
Girishanthy Krishnarajah, MPH, MBA/MS; Monali Bhosle, PhD; Richard Chapman, PhD
A comparison of health care costs in patients with diabetes who do not initially respond to oral therapy suggests that it might be appropriate and clinically beneficial for providers to consider adding another oral agent, rather than up-titrating the current medication, particularly beyond intermediate dose levels